Resectin Protein Fragments for Extracellular Signaling Discovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aminoacyl-tRNA synthetases (AARSs) have been primarily studied for their role in protein translation, but their protein fragments, known as resectins, possess unexpected extracellular signaling activities that are not fully understood or utilized in diagnostic or therapeutic applications.
Innovation Solution
Identification and characterization of resectin protein fragments from AARSs, including Leucyl tRNA synthetases, for their non-canonical biological activities, such as extracellular signaling, and development of biotherapeutic, diagnostic, and drug discovery agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If full-length AARS proteins are studied for their canonical aminoacylation function, then the understanding of protein translation is improved, but the unexpected extracellular signaling activities of AARS fragments remain undiscovered and unused
Solution Approach 1:
The patent systematically segments AARS proteins into various fragments through proteolytic processing and alternative splicing to discover novel biological activities. This segmentation approach reveals that AARS fragments possess unexpected extracellular signaling functions distinct from the canonical aminoacylation activity of full-length proteins, thereby resolving the contradiction between studying full-length proteins and discovering fragment activities.
Solution Approach 2:
The patent extracts and isolates specific AARS fragments from their parental full-length protein sequences through proteolytic cleavage and purification processes. This extraction enables the discovery and characterization of novel extracellular signaling activities in fragments that were previously masked or unrecognized in the context of full-length proteins, addressing the loss of information about unknown biological activities.
2Reliability
If AARS fragments are purified and tested for novel activities, then unexpected extracellular signaling activities are discovered, but the time and resources required for systematic analysis increase significantly
Solution Approach 1:
The patent employs preliminary bioinformatic predictions and in silico analyses to identify potential AARS fragments and their processing sites before conducting wet-lab experiments. This preliminary computational screening reduces the search space and guides subsequent experimental purification and characterization efforts, thereby reducing the time and resources required while maintaining high reliability in discovering novel activities.
Solution Approach 2:
The patent demonstrates that AARS fragments serve multiple functions beyond their canonical role in protein translation, including extracellular signaling, cell proliferation regulation, and differentiation control. This multi-functionality discovery through systematic fragment analysis justifies the investment of time and resources by revealing therapeutic potentials in inflammatory, hematological, and neurodegenerative diseases.
3Adaptability or versatility
If resectins are developed as therapeutic agents, then treatment options for various diseases are expanded, but the complexity of identifying and characterizing suitable fragments increases
Solution Approach 1:
The patent identifies specific local regions and domains within AARS proteins that possess distinct functional properties suitable for therapeutic applications. By characterizing the local quality of different AARS fragments, the patent enables selective development of fragments with desired therapeutic properties for specific disease indications, thereby expanding adaptability while managing identification complexity through targeted analysis.
Solution Approach 2:
The patent systematically varies parameters such as fragment size, amino acid sequence, and structural conformation to optimize therapeutic properties of resectins. By changing these parameters and evaluating their effects on biological activity, stability, and therapeutic efficacy, the patent facilitates the development of suitable therapeutic fragments while providing a structured approach to manage the complexity of fragment identification and characterization.
Data Source
AI summary
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.